Novo Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NOVO, and when can generic versions of NOVO drugs launch?
NOVO has twelve approved drugs.
There are fifty-four US patents protecting NOVO drugs.
There are five hundred and twelve patent family members on NOVO drugs in forty-four countries and one hundred and eighteen supplementary protection certificates in seventeen countries.
Summary for Novo
| International Patents: | 512 |
| US Patents: | 54 |
| Tradenames: | 12 |
| Ingredients: | 8 |
| NDAs: | 12 |
Drugs and US Patents for Novo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | RX | Yes | Yes | 8,672,898 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-004 | Jun 4, 2021 | RX | Yes | Yes | 10,888,605 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Novo | RYBELSUS | semaglutide | TABLET;ORAL | 213051-001 | Sep 20, 2019 | RX | Yes | No | 8,129,343 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Novo | WEGOVY | semaglutide | SOLUTION;SUBCUTANEOUS | 215256-001 | Jun 4, 2021 | RX | Yes | Yes | 8,129,343 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | RX | Yes | Yes | 8,579,869 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | RE46363*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | 8,672,898 | See Plans and Pricing |
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-002 | Apr 9, 2019 | 9,486,588 | See Plans and Pricing |
| Novo Nordisk Inc | PRANDIMET | metformin hydrochloride; repaglinide | TABLET;ORAL | 022386-001 | Jun 23, 2008 | RE37035 | See Plans and Pricing |
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | 9,486,588 | See Plans and Pricing |
| Novo | OZEMPIC | semaglutide | SOLUTION;SUBCUTANEOUS | 209637-001 | Dec 5, 2017 | 6,899,699 | See Plans and Pricing |
| Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | RE41956*PED | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | 2016-12-12 |
| ➤ Subscribe | Vaginal Tablets | 10 mcg | ➤ Subscribe | 2013-01-02 |
| ➤ Subscribe | Tablets | 1 mg/500 mg and 2 mg/500 mg | ➤ Subscribe | 2009-04-09 |
International Patents for Novo Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Germany | 602005017182 | See Plans and Pricing |
| Poland | 192359 | See Plans and Pricing |
| Ukraine | 113976 | See Plans and Pricing |
| Russian Federation | 2270198 | See Plans and Pricing |
| Russian Federation | 2671406 | See Plans and Pricing |
| Japan | 2004516895 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novo Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0398460 | 12/2004 | Austria | See Plans and Pricing | PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211 |
| 1863839 | C01863839/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018 |
| 2782584 | 301153 | Netherlands | See Plans and Pricing | PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406 |
| 2597103 | 2017/015 | Ireland | See Plans and Pricing | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912 |
| 1532149 | C300569 | Netherlands | See Plans and Pricing | PRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN COMBINATIE MET METFORMINEHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/12/780/001-028 20120720 |
| 1453521 | 93156 | Luxembourg | See Plans and Pricing | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
